Major liver resection, systemic fibrinolytic activity, and the impact of tranexamic acid.

ABSTRACT:

Background

Hyperfibrinolysis may occur due to systemic inflammation or hepatic injury that occurs during liver resection. Tranexamic acid (TXA) is an antifibrinolytic agent that decreases bleeding in various settings, but has not been well studied in patients undergoing liver resection.

Methods

In this prospective, phase II trial, 18 patients undergoing major liver resection were sequentially assigned to one of three cohorts: (i) Control (no TXA); (ii) TXA Dose I - 1 g bolus followed by 1 g infusion over 8 h; (iii) TXA Dose II - 1 g bolus followed by 10 mg/kg/hr until the end of surgery. Serial blood samples were collected for thromboelastography (TEG), coagulation components and TXA concentration.

Results

No abnormalities in hemostatic function were identified on TEG

SUBMITTER: Karanicolas PJ 

PROVIDER: S-EPMC5144548 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature